Advanced Filters
noise

Greenwood Village, Colorado Clinical Trials

A listing of Greenwood Village, Colorado clinical trials actively recruiting patient volunteers.

Found 260 clinical trials
A Anthony Giuffrida

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

This is a double-blind, saline-controlled, and randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed …

18 - 60 years of age All Phase 2

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).

18 years of age All Phase 2
J Jasmine Galloway, B.S.

Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

The purpose of this study is to compare two biologic methods for the treatment of articular cartilage defects in the knee. The first method, microfracture, is the standard of care and is routinely used to recruit cells from the subchondral bone marrow to the site of cartilage loss. The second …

18 - 50 years of age All Phase N/A

Alveolar Macrophage Programming Following Endotoxin Exposure

The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory …

18 - 50 years of age All Phase N/A
J Justin Wade

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)

The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)

18 years of age All Phase 1
C China Whitwer

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors …

18 - 89 years of age All Phase 1/2
K Kate Freeman

Ovitex in Paraesophageal and Large Hiatal Hernia Repair

The purpose of the study is to evaluate the success of hiatal hernia repairs in patients with large (>5cm) or paraesophageal hernias when Ovitex LPR mesh used during the repair.

18 - 85 years of age All Phase N/A
J Julia Etchart

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.

18 years of age All Phase 1/2

Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation

The purpose of this study is to assess the effectiveness of prophylactic oxytocin on hemorrhage rates for second trimester dilation and evacuation (D&E) in the clinic setting.

18 - 55 years of age Female Phase 2

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

18 years of age All Phase 1

Simplify language using AI